BAY1436032

DRUG2 trials

Sponsors

Bayer

Conditions

Leukemia, Myeloid, AcuteSolid Tumors

Phase 1

Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors

CompletedNCT02746081

BayerSolid Tumors

Start: 2016-05-26End: 2024-12-03Updated: 2024-12-18

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

CompletedNCT03127735

BayerLeukemia, Myeloid, Acute

Start: 2017-06-14End: 2019-03-15Updated: 2019-05-14

Related Papers

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

HemaSphere2021-06-0112 citations

Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032

Cancers2020-10-2913 citations